Review



recombinant bmp6  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Proteintech recombinant bmp6
    Recombinant Bmp6, supplied by Proteintech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant bmp6/product/Proteintech
    Average 90 stars, based on 1 article reviews
    recombinant bmp6 - by Bioz Stars, 2026-02
    90/100 stars

    Images



    Similar Products

    95
    R&D Systems bmp6
    Bmp6, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bmp6/product/R&D Systems
    Average 95 stars, based on 1 article reviews
    bmp6 - by Bioz Stars, 2026-02
    95/100 stars
      Buy from Supplier

    94
    Novus Biologicals bmp6
    Bmp6, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bmp6/product/Novus Biologicals
    Average 94 stars, based on 1 article reviews
    bmp6 - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    90
    Proteintech recombinant bmp6
    Recombinant Bmp6, supplied by Proteintech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant bmp6/product/Proteintech
    Average 90 stars, based on 1 article reviews
    recombinant bmp6 - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    90
    PeproTech recombinant human bone morphogenetic protein 6 (bmp6)
    Recombinant Human Bone Morphogenetic Protein 6 (Bmp6), supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human bone morphogenetic protein 6 (bmp6)/product/PeproTech
    Average 90 stars, based on 1 article reviews
    recombinant human bone morphogenetic protein 6 (bmp6) - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    94
    R&D Systems mouse bmp6
    BMP signaling in NPCs increases the ratio of young adult type B cells to type E cells (A) P0 NPC cultures maintained for 5 DIV in the presence of 10% fetal bovine serum (FBS) and then for 1 day without FBS and in the absence or presence of BMP2 (20 ng/ml) or <t>BMP6</t> (20 ng/ml) were subjected to RNA-seq analysis. (B) Volcano plots showing changes in gene expression induced by BMP2 or BMP6 treatment. Differentially expressed genes (DEGs) that were upregulated by BMP2 or BMP6 treatment (edgeR: p < 0.05, log2[fold change] > 0.585) are shown in pink, whereas those downregulated by BMP2 or BMP6 (upregulated in the control) (edgeR: p < 0.05, log2[fold change] < –0.585) are shown in light blue. (C) Gene-set enrichment analysis (GSEA) for E16.5 B-like versus E-like cells with DEGs found to be upregulated or downregulated by BMP2 or BMP6 in (B). BMP2- or BMP6-upregulated DEGs were enriched in B-like cells, whereas BMP2- or BMP6- downregulated DEGs were enriched in E-like cells. NES, normalized enrichment score; FDR, false discovery rate. (D) GSEA for BMP2- or BMP6-treated NPC cultures versus control cultures with adult type B cell (qNSC) and adult type E cell gene sets (Shah et al., 2018). Adult type B cell genes were enriched in BMP2- or BMP6-treated cultures compared with control cultures, whereas adult type E cell genes were enriched in control cultures compared with BMP2- or BMP6-treated cultures. (E) Scheme for virus infection experiments. In utero infection (IUI) was performed at E14.5 with the indicated lentivirus cocktail (FU-T2A-mScarlet-W and FU-GeneX-T2A- EGFP-W lentiviruses), and mice were subjected to immunohistofluorescence staining at P25–30. OE, overexpression. (F) The lentiviruses FU-T2A-mScarlet-W and FU-ALK2QD-T2A-EGFP-W were injected into the lateral ventricle of embryos at E14.5, and the resulting mice were subjected to immunofluorescence analysis at P28–30. Brain sections were stained for EGFP, mScarlet, GFAP, and S100β. Light blue and pink arrowheads indicate young adult type B cells and type E cells, respectively. Young adult type B cells were defined as GFAP + cells with apical attachment in the V-SVZ of the lateral wall, and type E cells as S100β + cells. Scale bars, 50 μm. (G) Proportions of young adult type B cells and type E cells among infected cells (control or ALK2QD overexpressing) in the V-SVZ determined from images as in (F). Cells positive for both mScarlet and EGFP were excluded from the analysis. Data are means ± SD ( n = 3 mice). *** p < 0.001, two-tailed Student’s t test. See also .
    Mouse Bmp6, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse bmp6/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    mouse bmp6 - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    90
    PeproTech recombinant human bmp6 (120-06)
    Primers used for real-time PCR
    Recombinant Human Bmp6 (120 06), supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human bmp6 (120-06)/product/PeproTech
    Average 90 stars, based on 1 article reviews
    recombinant human bmp6 (120-06) - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    95
    R&D Systems human bmp6
    ( A ) Relative transcript levels of type I (ALK1, ALK2, ALK3, ALK6) and type II (BMPR2, ACVR2A, ACVR2B) BMP receptors in primary human foreskin fibroblasts (HFF-1) were determined by RT-qPCR. ( B ) Schematic representation of the workflow. After 2 h of serum starvation, HFF-1 were stimulated with IFNβ (5 ng/ml), BMP4 (18 nM), <t>BMP6</t> (18 nM), BMP9 (3 nM), BMP15 (18 nM), or Activin B (4 nM), followed by either immunoblot analysis 1 h post stimulation or RNA extraction from cell lysates and RT-qPCR 6 h post stimulation. GAPDH transcript levels were used for normalization. ( C ) Immunoblot analysis of HFF-1 upon stimulation to determine phosphorylation levels of respective signaling components. ( D ) Transcript levels of the BMP-responsive genes Id1 and Id3 upon stimulation with the indicated ligands. ( E ) Transcript levels of the ISGs Isg15 , Irf9 , Ifi6 , and Stat2 upon stimulation with the indicated ligands. Data information: ( A , B ) The Experiment was performed two independent times, one representative is shown. ( D , E) The experiment was performed three independent times, one representative is shown. Data are shown as mean ± SD. .
    Human Bmp6, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human bmp6/product/R&D Systems
    Average 95 stars, based on 1 article reviews
    human bmp6 - by Bioz Stars, 2026-02
    95/100 stars
      Buy from Supplier

    90
    PeproTech recombinant human bmp6
    ( A ) Relative transcript levels of type I (ALK1, ALK2, ALK3, ALK6) and type II (BMPR2, ACVR2A, ACVR2B) BMP receptors in primary human foreskin fibroblasts (HFF-1) were determined by RT-qPCR. ( B ) Schematic representation of the workflow. After 2 h of serum starvation, HFF-1 were stimulated with IFNβ (5 ng/ml), BMP4 (18 nM), <t>BMP6</t> (18 nM), BMP9 (3 nM), BMP15 (18 nM), or Activin B (4 nM), followed by either immunoblot analysis 1 h post stimulation or RNA extraction from cell lysates and RT-qPCR 6 h post stimulation. GAPDH transcript levels were used for normalization. ( C ) Immunoblot analysis of HFF-1 upon stimulation to determine phosphorylation levels of respective signaling components. ( D ) Transcript levels of the BMP-responsive genes Id1 and Id3 upon stimulation with the indicated ligands. ( E ) Transcript levels of the ISGs Isg15 , Irf9 , Ifi6 , and Stat2 upon stimulation with the indicated ligands. Data information: ( A , B ) The Experiment was performed two independent times, one representative is shown. ( D , E) The experiment was performed three independent times, one representative is shown. Data are shown as mean ± SD. .
    Recombinant Human Bmp6, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human bmp6/product/PeproTech
    Average 90 stars, based on 1 article reviews
    recombinant human bmp6 - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    Image Search Results


    BMP signaling in NPCs increases the ratio of young adult type B cells to type E cells (A) P0 NPC cultures maintained for 5 DIV in the presence of 10% fetal bovine serum (FBS) and then for 1 day without FBS and in the absence or presence of BMP2 (20 ng/ml) or BMP6 (20 ng/ml) were subjected to RNA-seq analysis. (B) Volcano plots showing changes in gene expression induced by BMP2 or BMP6 treatment. Differentially expressed genes (DEGs) that were upregulated by BMP2 or BMP6 treatment (edgeR: p < 0.05, log2[fold change] > 0.585) are shown in pink, whereas those downregulated by BMP2 or BMP6 (upregulated in the control) (edgeR: p < 0.05, log2[fold change] < –0.585) are shown in light blue. (C) Gene-set enrichment analysis (GSEA) for E16.5 B-like versus E-like cells with DEGs found to be upregulated or downregulated by BMP2 or BMP6 in (B). BMP2- or BMP6-upregulated DEGs were enriched in B-like cells, whereas BMP2- or BMP6- downregulated DEGs were enriched in E-like cells. NES, normalized enrichment score; FDR, false discovery rate. (D) GSEA for BMP2- or BMP6-treated NPC cultures versus control cultures with adult type B cell (qNSC) and adult type E cell gene sets (Shah et al., 2018). Adult type B cell genes were enriched in BMP2- or BMP6-treated cultures compared with control cultures, whereas adult type E cell genes were enriched in control cultures compared with BMP2- or BMP6-treated cultures. (E) Scheme for virus infection experiments. In utero infection (IUI) was performed at E14.5 with the indicated lentivirus cocktail (FU-T2A-mScarlet-W and FU-GeneX-T2A- EGFP-W lentiviruses), and mice were subjected to immunohistofluorescence staining at P25–30. OE, overexpression. (F) The lentiviruses FU-T2A-mScarlet-W and FU-ALK2QD-T2A-EGFP-W were injected into the lateral ventricle of embryos at E14.5, and the resulting mice were subjected to immunofluorescence analysis at P28–30. Brain sections were stained for EGFP, mScarlet, GFAP, and S100β. Light blue and pink arrowheads indicate young adult type B cells and type E cells, respectively. Young adult type B cells were defined as GFAP + cells with apical attachment in the V-SVZ of the lateral wall, and type E cells as S100β + cells. Scale bars, 50 μm. (G) Proportions of young adult type B cells and type E cells among infected cells (control or ALK2QD overexpressing) in the V-SVZ determined from images as in (F). Cells positive for both mScarlet and EGFP were excluded from the analysis. Data are means ± SD ( n = 3 mice). *** p < 0.001, two-tailed Student’s t test. See also .

    Journal: bioRxiv

    Article Title: Embryonic diversification of adult neural stem cells and ependymal cells

    doi: 10.1101/2024.05.12.593751

    Figure Lengend Snippet: BMP signaling in NPCs increases the ratio of young adult type B cells to type E cells (A) P0 NPC cultures maintained for 5 DIV in the presence of 10% fetal bovine serum (FBS) and then for 1 day without FBS and in the absence or presence of BMP2 (20 ng/ml) or BMP6 (20 ng/ml) were subjected to RNA-seq analysis. (B) Volcano plots showing changes in gene expression induced by BMP2 or BMP6 treatment. Differentially expressed genes (DEGs) that were upregulated by BMP2 or BMP6 treatment (edgeR: p < 0.05, log2[fold change] > 0.585) are shown in pink, whereas those downregulated by BMP2 or BMP6 (upregulated in the control) (edgeR: p < 0.05, log2[fold change] < –0.585) are shown in light blue. (C) Gene-set enrichment analysis (GSEA) for E16.5 B-like versus E-like cells with DEGs found to be upregulated or downregulated by BMP2 or BMP6 in (B). BMP2- or BMP6-upregulated DEGs were enriched in B-like cells, whereas BMP2- or BMP6- downregulated DEGs were enriched in E-like cells. NES, normalized enrichment score; FDR, false discovery rate. (D) GSEA for BMP2- or BMP6-treated NPC cultures versus control cultures with adult type B cell (qNSC) and adult type E cell gene sets (Shah et al., 2018). Adult type B cell genes were enriched in BMP2- or BMP6-treated cultures compared with control cultures, whereas adult type E cell genes were enriched in control cultures compared with BMP2- or BMP6-treated cultures. (E) Scheme for virus infection experiments. In utero infection (IUI) was performed at E14.5 with the indicated lentivirus cocktail (FU-T2A-mScarlet-W and FU-GeneX-T2A- EGFP-W lentiviruses), and mice were subjected to immunohistofluorescence staining at P25–30. OE, overexpression. (F) The lentiviruses FU-T2A-mScarlet-W and FU-ALK2QD-T2A-EGFP-W were injected into the lateral ventricle of embryos at E14.5, and the resulting mice were subjected to immunofluorescence analysis at P28–30. Brain sections were stained for EGFP, mScarlet, GFAP, and S100β. Light blue and pink arrowheads indicate young adult type B cells and type E cells, respectively. Young adult type B cells were defined as GFAP + cells with apical attachment in the V-SVZ of the lateral wall, and type E cells as S100β + cells. Scale bars, 50 μm. (G) Proportions of young adult type B cells and type E cells among infected cells (control or ALK2QD overexpressing) in the V-SVZ determined from images as in (F). Cells positive for both mScarlet and EGFP were excluded from the analysis. Data are means ± SD ( n = 3 mice). *** p < 0.001, two-tailed Student’s t test. See also .

    Article Snippet: Recombinant human/mouse/rat BMP2 or mouse BMP6 (R&D Systems) was added to cultures at 50 ng/ml in differentiation medium after incubation of the cells for 5 DIV in proliferation medium.

    Techniques: RNA Sequencing, Gene Expression, Control, Virus, Infection, In Utero, Immunohistofluorescence, Staining, Over Expression, Injection, Immunofluorescence, Two Tailed Test

    Primers used for real-time PCR

    Journal: Journal of Clinical and Translational Hepatology

    Article Title: Serum Iron Overload Activates the SMAD Pathway and Hepcidin Expression of Hepatocytes via SMURF1

    doi: 10.14218/JCTH.2023.00440

    Figure Lengend Snippet: Primers used for real-time PCR

    Article Snippet: Recombinant human BMP6 (120-06) was purchased from PeproTech (Rocky Hill, NJ, USA).

    Techniques:

    (A) The pSMAD1/5 level was analyzed in primary mouse hepatocytes (left) and HepG2 cells (right) treated with increasing concentrations of BMP6 with (+) or without (–) 2 mg/mL of Holo-Tf in serum-free medium for 2 h. n =2 independent experiments. (B) The mRNA expression of Hamp and Id1 was analyzed in primary mouse hepatocytes treated with increasing concentrations of BMP6 with (+) or without (–) Holo-Tf in serum-free medium for 6 h. * p <0.05; data are presented as the means±standard deviations. (C) The mRNA expression of HAMP and ID1 was analyzed in HepG2 cells treated with increasing concentrations of BMP6 with (+) or without (–) Holo-Tf in serum-free medium for 6 h. * p <0.05; data are presented as the means±standard deviations. (D) The pSMAD1/5 level was analyzed in primary mouse hepatocytes pretreated with (+) or without (–) LDN193189 (10 µM) for 1 h with 5% serum, and 2 mg/mL of Holo-Tf with (+) or without (–) LDN193189 was added at the indicated times. n =3 independent experiments. (E) The pSMAD1/5 level was analyzed in HepG2 cells pretreated with (+) or without (–) LDN193189 (10 µM) for 1 h without serum, and 2 mg/mL of Holo-Tf or 5% serum with (+) or without (–) LDN193189 was added for 1 h. n =2 independent experiments. (F) The pSMAD1/5 level was analyzed in BMPR-1A-knocked-down (+) and negative control (–) HepG2 cells supplemented with (+) or without (–) 2 mg/mL Holo-Tf in the presence (+) or absence (–) of 5% serum for 1 h. n =2 independent experiments. Unprocessed blots are provided in . BMP6, bone morphogenetic protein 6; BMPR-1A, bone morphogenetic protein receptor type-1A; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HAMP, hepcidin; Holo-Tf, holo-transferrin; ID1, DNA-binding protein inhibitor ID-1; pSMAD1/5, phosphorylated SMAD1 and SMAD5 protein.

    Journal: Journal of Clinical and Translational Hepatology

    Article Title: Serum Iron Overload Activates the SMAD Pathway and Hepcidin Expression of Hepatocytes via SMURF1

    doi: 10.14218/JCTH.2023.00440

    Figure Lengend Snippet: (A) The pSMAD1/5 level was analyzed in primary mouse hepatocytes (left) and HepG2 cells (right) treated with increasing concentrations of BMP6 with (+) or without (–) 2 mg/mL of Holo-Tf in serum-free medium for 2 h. n =2 independent experiments. (B) The mRNA expression of Hamp and Id1 was analyzed in primary mouse hepatocytes treated with increasing concentrations of BMP6 with (+) or without (–) Holo-Tf in serum-free medium for 6 h. * p <0.05; data are presented as the means±standard deviations. (C) The mRNA expression of HAMP and ID1 was analyzed in HepG2 cells treated with increasing concentrations of BMP6 with (+) or without (–) Holo-Tf in serum-free medium for 6 h. * p <0.05; data are presented as the means±standard deviations. (D) The pSMAD1/5 level was analyzed in primary mouse hepatocytes pretreated with (+) or without (–) LDN193189 (10 µM) for 1 h with 5% serum, and 2 mg/mL of Holo-Tf with (+) or without (–) LDN193189 was added at the indicated times. n =3 independent experiments. (E) The pSMAD1/5 level was analyzed in HepG2 cells pretreated with (+) or without (–) LDN193189 (10 µM) for 1 h without serum, and 2 mg/mL of Holo-Tf or 5% serum with (+) or without (–) LDN193189 was added for 1 h. n =2 independent experiments. (F) The pSMAD1/5 level was analyzed in BMPR-1A-knocked-down (+) and negative control (–) HepG2 cells supplemented with (+) or without (–) 2 mg/mL Holo-Tf in the presence (+) or absence (–) of 5% serum for 1 h. n =2 independent experiments. Unprocessed blots are provided in . BMP6, bone morphogenetic protein 6; BMPR-1A, bone morphogenetic protein receptor type-1A; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HAMP, hepcidin; Holo-Tf, holo-transferrin; ID1, DNA-binding protein inhibitor ID-1; pSMAD1/5, phosphorylated SMAD1 and SMAD5 protein.

    Article Snippet: Recombinant human BMP6 (120-06) was purchased from PeproTech (Rocky Hill, NJ, USA).

    Techniques: Expressing, Negative Control, Binding Assay

    (A) The protein expression levels of SMAD6, SMAD7, SMURF1, and SMURF2 were analyzed in HepG2 cells incubated with 2 mg/mL of Holo-Tf in serum at the indicated times. n =3 independent experiments. (B) The protein expression of SMURF1 and SMURF2 was analyzed in primary mouse hepatocytes treated with the indicated concentrations of Holo-Tf for 30 m. n =3 independent experiments. (C) The protein expression levels of SMAD1, BMPR-1A, and BMPR-2 were analyzed in HepG2 cells incubated with 2 mg/mL of Holo-Tf in serum at the indicated times. n =3 independent experiments. (D) The protein expression of SMURF1, SMAD1, BMPR-1A, and BMPR-2 was analyzed in primary mouse hepatocytes treated with increasing concentrations of BMP6 in the presence (+) or absence (–) of 2 mg/mL of Holo-Tf in serum-free medium for 2 h. n =3 independent experiments. (E) The pSMAD1/5 level and the protein expression of SMAD1 and SMURF1 were analyzed in SMURF1-transfected (+) and mock-transfected (–) HepG2 cells treated with increasing concentrations of BMP6 in serum-free medium for 2 h. n =2 independent experiments. (F) The pSMAD1/5 level and the protein expression of SMAD1 and SMURF1 were analyzed in SMURF1-knocked-down (+) and negative control (–) HepG2 cells treated with increasing concentrations of BMP6 in serum-free medium for 2 h. n =2 independent experiments. Unprocessed blots are provided in . BMP6, bone morphogenetic protein 6; BMPR-1A, bone morphogenetic protein receptor type-1A; BMPR-2, bone morphogenetic protein receptor type-2; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; Holo-Tf, holo-transferrin; SMAD1: SMA and mothers against decapentaplegic homolog 1; SMAD6: SMA and mothers against decapentaplegic homolog 6; SMAD7: SMA and mothers against decapentaplegic homolog 7; SMURF1, E3 ubiquitin-protein ligase 1; SMURF2, E3 ubiquitin-protein ligase 2.

    Journal: Journal of Clinical and Translational Hepatology

    Article Title: Serum Iron Overload Activates the SMAD Pathway and Hepcidin Expression of Hepatocytes via SMURF1

    doi: 10.14218/JCTH.2023.00440

    Figure Lengend Snippet: (A) The protein expression levels of SMAD6, SMAD7, SMURF1, and SMURF2 were analyzed in HepG2 cells incubated with 2 mg/mL of Holo-Tf in serum at the indicated times. n =3 independent experiments. (B) The protein expression of SMURF1 and SMURF2 was analyzed in primary mouse hepatocytes treated with the indicated concentrations of Holo-Tf for 30 m. n =3 independent experiments. (C) The protein expression levels of SMAD1, BMPR-1A, and BMPR-2 were analyzed in HepG2 cells incubated with 2 mg/mL of Holo-Tf in serum at the indicated times. n =3 independent experiments. (D) The protein expression of SMURF1, SMAD1, BMPR-1A, and BMPR-2 was analyzed in primary mouse hepatocytes treated with increasing concentrations of BMP6 in the presence (+) or absence (–) of 2 mg/mL of Holo-Tf in serum-free medium for 2 h. n =3 independent experiments. (E) The pSMAD1/5 level and the protein expression of SMAD1 and SMURF1 were analyzed in SMURF1-transfected (+) and mock-transfected (–) HepG2 cells treated with increasing concentrations of BMP6 in serum-free medium for 2 h. n =2 independent experiments. (F) The pSMAD1/5 level and the protein expression of SMAD1 and SMURF1 were analyzed in SMURF1-knocked-down (+) and negative control (–) HepG2 cells treated with increasing concentrations of BMP6 in serum-free medium for 2 h. n =2 independent experiments. Unprocessed blots are provided in . BMP6, bone morphogenetic protein 6; BMPR-1A, bone morphogenetic protein receptor type-1A; BMPR-2, bone morphogenetic protein receptor type-2; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; Holo-Tf, holo-transferrin; SMAD1: SMA and mothers against decapentaplegic homolog 1; SMAD6: SMA and mothers against decapentaplegic homolog 6; SMAD7: SMA and mothers against decapentaplegic homolog 7; SMURF1, E3 ubiquitin-protein ligase 1; SMURF2, E3 ubiquitin-protein ligase 2.

    Article Snippet: Recombinant human BMP6 (120-06) was purchased from PeproTech (Rocky Hill, NJ, USA).

    Techniques: Expressing, Incubation, Transfection, Negative Control

    (A) Prussian blue staining, the serum Fe concentration, and the mRNA expression of Hamp , Bmp6, and Smurf1 in the serum iron overload mouse model were analyzed at the indicated times ( n =3–4 per group). * p <0.05; data are presented as the means±standard deviations. (B) The pSMAD1/5 level and the protein expression of SMURF1, SMAD1, BMPR-1A, BMPR-2, SMURF2, SMAD6, SMAD7, TFR2, and FTH1 were analyzed in a serum iron overload mouse model at the indicated times. (C) The pSMAD1/5 level and the protein expression of SMURF1, SMAD1, BMPR-1A, BMPR-2, SMURF2, TFR2, and FTH1 in the liver iron overload mouse model were analyzed in liver iron overload mouse model. (D) Prussian blue staining, the serum Fe concentration, and Hamp , Bmp6 , and Smurf1 mRNA expression in the liver iron overload mouse model were analyzed at the indicated times ( n =5 per group). * p <0.05; data are presented as the means±standard deviations. Unprocessed blots are provided in . BMP6, bone morphogenetic protein 6; BMPR-1A, bone morphogenetic protein receptor type-1A; BMPR-2, bone morphogenetic protein receptor type-2; FTH1, ferritin heavy chain; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HAMP, hepcidin; Holo-Tf, holo-transferrin; pSMAD1/5, phosphorylated SMAD1 and SMAD5 protein; SMAD1: SMA and mothers against decapentaplegic homolog 1; SMAD6: SMA and mothers against decapentaplegic homolog 6; SMAD7, SMA and mothers against decapentaplegic homolog 7; SMURF1, E3 ubiquitin-protein ligase 1; SMURF2, E3 ubiquitin-protein ligase 2; TFR2, transferrin receptor protein 2.

    Journal: Journal of Clinical and Translational Hepatology

    Article Title: Serum Iron Overload Activates the SMAD Pathway and Hepcidin Expression of Hepatocytes via SMURF1

    doi: 10.14218/JCTH.2023.00440

    Figure Lengend Snippet: (A) Prussian blue staining, the serum Fe concentration, and the mRNA expression of Hamp , Bmp6, and Smurf1 in the serum iron overload mouse model were analyzed at the indicated times ( n =3–4 per group). * p <0.05; data are presented as the means±standard deviations. (B) The pSMAD1/5 level and the protein expression of SMURF1, SMAD1, BMPR-1A, BMPR-2, SMURF2, SMAD6, SMAD7, TFR2, and FTH1 were analyzed in a serum iron overload mouse model at the indicated times. (C) The pSMAD1/5 level and the protein expression of SMURF1, SMAD1, BMPR-1A, BMPR-2, SMURF2, TFR2, and FTH1 in the liver iron overload mouse model were analyzed in liver iron overload mouse model. (D) Prussian blue staining, the serum Fe concentration, and Hamp , Bmp6 , and Smurf1 mRNA expression in the liver iron overload mouse model were analyzed at the indicated times ( n =5 per group). * p <0.05; data are presented as the means±standard deviations. Unprocessed blots are provided in . BMP6, bone morphogenetic protein 6; BMPR-1A, bone morphogenetic protein receptor type-1A; BMPR-2, bone morphogenetic protein receptor type-2; FTH1, ferritin heavy chain; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HAMP, hepcidin; Holo-Tf, holo-transferrin; pSMAD1/5, phosphorylated SMAD1 and SMAD5 protein; SMAD1: SMA and mothers against decapentaplegic homolog 1; SMAD6: SMA and mothers against decapentaplegic homolog 6; SMAD7, SMA and mothers against decapentaplegic homolog 7; SMURF1, E3 ubiquitin-protein ligase 1; SMURF2, E3 ubiquitin-protein ligase 2; TFR2, transferrin receptor protein 2.

    Article Snippet: Recombinant human BMP6 (120-06) was purchased from PeproTech (Rocky Hill, NJ, USA).

    Techniques: Staining, Concentration Assay, Expressing

    ( A ) Relative transcript levels of type I (ALK1, ALK2, ALK3, ALK6) and type II (BMPR2, ACVR2A, ACVR2B) BMP receptors in primary human foreskin fibroblasts (HFF-1) were determined by RT-qPCR. ( B ) Schematic representation of the workflow. After 2 h of serum starvation, HFF-1 were stimulated with IFNβ (5 ng/ml), BMP4 (18 nM), BMP6 (18 nM), BMP9 (3 nM), BMP15 (18 nM), or Activin B (4 nM), followed by either immunoblot analysis 1 h post stimulation or RNA extraction from cell lysates and RT-qPCR 6 h post stimulation. GAPDH transcript levels were used for normalization. ( C ) Immunoblot analysis of HFF-1 upon stimulation to determine phosphorylation levels of respective signaling components. ( D ) Transcript levels of the BMP-responsive genes Id1 and Id3 upon stimulation with the indicated ligands. ( E ) Transcript levels of the ISGs Isg15 , Irf9 , Ifi6 , and Stat2 upon stimulation with the indicated ligands. Data information: ( A , B ) The Experiment was performed two independent times, one representative is shown. ( D , E) The experiment was performed three independent times, one representative is shown. Data are shown as mean ± SD. .

    Journal: EMBO Reports

    Article Title: Novel role of bone morphogenetic protein 9 in innate host responses to HCMV infection

    doi: 10.1038/s44319-024-00072-2

    Figure Lengend Snippet: ( A ) Relative transcript levels of type I (ALK1, ALK2, ALK3, ALK6) and type II (BMPR2, ACVR2A, ACVR2B) BMP receptors in primary human foreskin fibroblasts (HFF-1) were determined by RT-qPCR. ( B ) Schematic representation of the workflow. After 2 h of serum starvation, HFF-1 were stimulated with IFNβ (5 ng/ml), BMP4 (18 nM), BMP6 (18 nM), BMP9 (3 nM), BMP15 (18 nM), or Activin B (4 nM), followed by either immunoblot analysis 1 h post stimulation or RNA extraction from cell lysates and RT-qPCR 6 h post stimulation. GAPDH transcript levels were used for normalization. ( C ) Immunoblot analysis of HFF-1 upon stimulation to determine phosphorylation levels of respective signaling components. ( D ) Transcript levels of the BMP-responsive genes Id1 and Id3 upon stimulation with the indicated ligands. ( E ) Transcript levels of the ISGs Isg15 , Irf9 , Ifi6 , and Stat2 upon stimulation with the indicated ligands. Data information: ( A , B ) The Experiment was performed two independent times, one representative is shown. ( D , E) The experiment was performed three independent times, one representative is shown. Data are shown as mean ± SD. .

    Article Snippet: Recombinant human BMP4 (#314-BP-010), human BMP6 (#507-BP-020), human BMP9 (#3209-BP-010), human BMP15 (#5096-BM-005), human Activin B (#659-AB-005), and the human/mouse anti-BMP9 antibody (#AF3209) were purchased from R&D Systems.

    Techniques: Quantitative RT-PCR, Western Blot, RNA Extraction

    ( A ) Presence of type I (ALK1, ALK2, ALK3) and type II (BMPR2) receptors in HFF-1 and 293T was verified by immunoblotting with the respective antibodies. Detection of GAPDH protein served as loading control. ( B ) Relative transcript levels of type I (ALK1, ALK2, ALK3, ALK6) and type II (BMPR2, ACVR2A, ACVR2B) BMP receptors in 293T were determined by RT-qPCR. ( C ) 293T were co-transfected with expression plasmids for the BRE-Luciferase reporter and a Renilla luciferase normalization control (EF1α-Renilla). 24 h post transfection, 293T were either stimulated with BMP9 (3 nM), or BMP9 (3 nM) incubated for 15 min at RT with an α-BMP9 antibody (1 µg/ml or 5 µg/ml) for 16 h, followed by a dual-luciferase assay readout. ( D ) 293T were co-transfected as in ( B ). 24 h post transfection, 293 T were either stimulated with BMP4 (18 nM), BMP6 (18 nM), BMP9 (3 nM), BMP15 (18 nM), or Activin B (4 nM), or with the ligands incubated for 15 min at RT with an α-BMP9 antibody (1 µg/ml) for 16 h, followed by a dual-luciferase assay readout. ( E ) HFF-1 were either mock, DMSO, Ruxolitinib (10 µM) or DMH1 (10 µM) treated for 2 h, followed by stimulation with IFNβ (5 ng/ml) or BMP4 (18 nM) for 2 h. Cells were lysed and lysates were subjected to immunoblot analysis with p-STAT1, STAT1, p-SMAD1/5/9, SMAD1, p-p38, p38, p-p44/42, p44/42, and Calnexin-specific antibodies. Data information: ( A – E ) Experiments were performed two independent times, one representative is shown. Luciferase fold induction was calculated by dividing Renilla-normalized values from stimulated samples by the corresponding values from unstimulated samples.

    Journal: EMBO Reports

    Article Title: Novel role of bone morphogenetic protein 9 in innate host responses to HCMV infection

    doi: 10.1038/s44319-024-00072-2

    Figure Lengend Snippet: ( A ) Presence of type I (ALK1, ALK2, ALK3) and type II (BMPR2) receptors in HFF-1 and 293T was verified by immunoblotting with the respective antibodies. Detection of GAPDH protein served as loading control. ( B ) Relative transcript levels of type I (ALK1, ALK2, ALK3, ALK6) and type II (BMPR2, ACVR2A, ACVR2B) BMP receptors in 293T were determined by RT-qPCR. ( C ) 293T were co-transfected with expression plasmids for the BRE-Luciferase reporter and a Renilla luciferase normalization control (EF1α-Renilla). 24 h post transfection, 293T were either stimulated with BMP9 (3 nM), or BMP9 (3 nM) incubated for 15 min at RT with an α-BMP9 antibody (1 µg/ml or 5 µg/ml) for 16 h, followed by a dual-luciferase assay readout. ( D ) 293T were co-transfected as in ( B ). 24 h post transfection, 293 T were either stimulated with BMP4 (18 nM), BMP6 (18 nM), BMP9 (3 nM), BMP15 (18 nM), or Activin B (4 nM), or with the ligands incubated for 15 min at RT with an α-BMP9 antibody (1 µg/ml) for 16 h, followed by a dual-luciferase assay readout. ( E ) HFF-1 were either mock, DMSO, Ruxolitinib (10 µM) or DMH1 (10 µM) treated for 2 h, followed by stimulation with IFNβ (5 ng/ml) or BMP4 (18 nM) for 2 h. Cells were lysed and lysates were subjected to immunoblot analysis with p-STAT1, STAT1, p-SMAD1/5/9, SMAD1, p-p38, p38, p-p44/42, p44/42, and Calnexin-specific antibodies. Data information: ( A – E ) Experiments were performed two independent times, one representative is shown. Luciferase fold induction was calculated by dividing Renilla-normalized values from stimulated samples by the corresponding values from unstimulated samples.

    Article Snippet: Recombinant human BMP4 (#314-BP-010), human BMP6 (#507-BP-020), human BMP9 (#3209-BP-010), human BMP15 (#5096-BM-005), human Activin B (#659-AB-005), and the human/mouse anti-BMP9 antibody (#AF3209) were purchased from R&D Systems.

    Techniques: Western Blot, Control, Quantitative RT-PCR, Transfection, Expressing, Luciferase, Incubation

    ( A ) Schematic representation of the workflow. After 2 h of serum starvation, HFF-1 were stimulated for 6 h with BMP4 (18 nM), BMP6 (18 nM), BMP9 (3 nM), BMP15 (18 nM), or Activin B (4 nM), or co-stimulated with IFNβ (5 ng/ml), followed by HCMV infection (MOI 0.5) for 16 h. Cells were fixed, nuclei were stained and cells were labeled for HCMV IE1 + cells as a readout for infection. ( B ) HCMV IE1 + cells normalized to total cell numbers and the untreated control (white column) in BMP/Activin stimulated samples (left panel) or with IFNβ co-stimulated samples (right panel). ( C ) HCMV IE1 + cells normalized to total cell numbers in cells pre-stimulated with either low (0.25 nM) or high (3 nM) concentrations of BMP9 (green symbols) or IFNβ co-stimulated with low and high concentrations of BMP9 (beige symbols). ( D ) HFF-1 were infected by centrifugal enhancement with HCMV WT (MOI 0.5) and supernatants of infected cells were collected in 6 h increments. 293T were co-transfected with expression plasmids for the BRE-Luciferase reporter and a Renilla luciferase normalization control. Twenty-four hours post transfection, 293T were either stimulated with supernatants from HCMV-infected cells, or supernatants from HCMV-infected cells incubated for 15 min at RT with an α-BMP9 antibody, for 16 h, followed by a dual-luciferase assay readout. Luciferase fold induction was calculated by dividing Renilla-normalized values from stimulated samples by the corresponding values from unstimulated samples. Data information: ( B ) Experiment was performed three independent times, one representative is shown. ( C , D ) Data are combined from two independent experiments. Student’s t test (unpaired, two-tailed), n.s. not significant, * P < 0.05, ** P < 0.01, *** P < 0.001. Data are shown as mean ± SD. .

    Journal: EMBO Reports

    Article Title: Novel role of bone morphogenetic protein 9 in innate host responses to HCMV infection

    doi: 10.1038/s44319-024-00072-2

    Figure Lengend Snippet: ( A ) Schematic representation of the workflow. After 2 h of serum starvation, HFF-1 were stimulated for 6 h with BMP4 (18 nM), BMP6 (18 nM), BMP9 (3 nM), BMP15 (18 nM), or Activin B (4 nM), or co-stimulated with IFNβ (5 ng/ml), followed by HCMV infection (MOI 0.5) for 16 h. Cells were fixed, nuclei were stained and cells were labeled for HCMV IE1 + cells as a readout for infection. ( B ) HCMV IE1 + cells normalized to total cell numbers and the untreated control (white column) in BMP/Activin stimulated samples (left panel) or with IFNβ co-stimulated samples (right panel). ( C ) HCMV IE1 + cells normalized to total cell numbers in cells pre-stimulated with either low (0.25 nM) or high (3 nM) concentrations of BMP9 (green symbols) or IFNβ co-stimulated with low and high concentrations of BMP9 (beige symbols). ( D ) HFF-1 were infected by centrifugal enhancement with HCMV WT (MOI 0.5) and supernatants of infected cells were collected in 6 h increments. 293T were co-transfected with expression plasmids for the BRE-Luciferase reporter and a Renilla luciferase normalization control. Twenty-four hours post transfection, 293T were either stimulated with supernatants from HCMV-infected cells, or supernatants from HCMV-infected cells incubated for 15 min at RT with an α-BMP9 antibody, for 16 h, followed by a dual-luciferase assay readout. Luciferase fold induction was calculated by dividing Renilla-normalized values from stimulated samples by the corresponding values from unstimulated samples. Data information: ( B ) Experiment was performed three independent times, one representative is shown. ( C , D ) Data are combined from two independent experiments. Student’s t test (unpaired, two-tailed), n.s. not significant, * P < 0.05, ** P < 0.01, *** P < 0.001. Data are shown as mean ± SD. .

    Article Snippet: Recombinant human BMP4 (#314-BP-010), human BMP6 (#507-BP-020), human BMP9 (#3209-BP-010), human BMP15 (#5096-BM-005), human Activin B (#659-AB-005), and the human/mouse anti-BMP9 antibody (#AF3209) were purchased from R&D Systems.

    Techniques: Infection, Staining, Labeling, Control, Transfection, Expressing, Luciferase, Incubation, Two Tailed Test